417 related articles for article (PubMed ID: 33680090)
1. Therapeutic strategies of recurrent glioblastoma and its molecular pathways 'Lock up the beast'.
El-Khayat SM; Arafat WO
Ecancermedicalscience; 2021; 15():1176. PubMed ID: 33680090
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
3. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
4. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
6. Barriers to overcoming immunotherapy resistance in glioblastoma.
Gillette JS; Wang EJ; Dowd RS; Toms SA
Front Med (Lausanne); 2023; 10():1175507. PubMed ID: 37275361
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.
Niedbała M; Malarz K; Sharma G; Kramer-Marek G; Kaspera W
Onco Targets Ther; 2022; 15():437-468. PubMed ID: 35509452
[TBL] [Abstract][Full Text] [Related]
8. Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies.
Fanelli GN; Grassini D; Ortenzi V; Pasqualetti F; Montemurro N; Perrini P; Naccarato AG; Scatena C
Genes (Basel); 2021 Mar; 12(3):. PubMed ID: 33804731
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Clinical Success and Molecular Mechanisms of Action of Novel Anti-glioblastoma Drugs: A Review.
Abdullaeva S; Chubarev V; Valeeva A; Preferanskaya N; Neganova M; Smolyarchuk E; Liu J; Sukocheva O; Samsonov M; Alyautdin R
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38299393
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?
Qin A; Musket A; Musich PR; Schweitzer JB; Xie Q
Neurooncol Adv; 2021; 3(1):vdab133. PubMed ID: 34806012
[TBL] [Abstract][Full Text] [Related]
11. Pathogenetic Features and Current Management of Glioblastoma.
Nguyen HM; Guz-Montgomery K; Lowe DB; Saha D
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670551
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapies for malignant glioma.
Boussiotis VA; Charest A
Oncogene; 2018 Mar; 37(9):1121-1141. PubMed ID: 29242608
[TBL] [Abstract][Full Text] [Related]
13. The future role of personalized medicine in the treatment of glioblastoma multiforme.
Li J; Di C; Mattox AK; Wu L; Adamson DC
Pharmgenomics Pers Med; 2010; 3():111-27. PubMed ID: 23226047
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Radiosurgery for Recurrent Glioblastoma Multiforme: A Retrospective Multi-Institutional Experience.
Lovo EE; Moreira A; Barahona KC; Ramirez J; Campos F; Tobar C; Caceros V; Sallabanda M; Sallabanda K
Cureus; 2021 Oct; 13(10):e18480. PubMed ID: 34754642
[TBL] [Abstract][Full Text] [Related]
15. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine associated with photodynamic therapy for glioblastoma treatment.
de Paula LB; Primo FL; Tedesco AC
Biophys Rev; 2017 Oct; 9(5):761-773. PubMed ID: 28823025
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions.
Ser MH; Webb MJ; Sener U; Campian JL
J Immunother Precis Oncol; 2024 May; 7(2):97-110. PubMed ID: 38721406
[TBL] [Abstract][Full Text] [Related]
18. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
19. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
[TBL] [Abstract][Full Text] [Related]
20. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.
Hanson JA; Hsu FP; Jacob AT; Bota DA; Alexandru D
Perm J; 2013; 17(4):68-74. PubMed ID: 24361023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
